Knut Stavem1, Leiv Sandvik, Jan Erikssen. 1. Medical Department, Akershus University Hospital, Lørenskog, Norway. knut.stavem@klinmed.uio.no
Abstract
STUDY OBJECTIVES: To determine if the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 0 (subjects at risk for COPD) provides information about long-term mortality risk. DESIGN, SETTING, AND PARTICIPANTS: From 1972 to 1975, clinical, physiologic, and biochemical parameters including respiratory symptoms, spirometry, and physical fitness were measured in 1,999 healthy men aged 40 to 59 years in an occupational cohort, of whom 1,623 had acceptable spirometry findings. In a proportional hazards model with follow-up until 2000, we assessed all-cause mortality according to GOLD stage 0, I, II, and III compared with "normal" subjects, after adjusting for known risk factors and potential confounders. RESULTS: After 26 years (range, 25 to 27 years), 615 men (38%) had died. In multivariate proportional hazards models, GOLD stage 0 subjects had a nonsignificantly increased hazard of death (hazard ratio [HR], 1.19; p = 0.21) after adjustment for age, smoking, physical fitness, body mass index, systolic BP, and serum cholesterol. Similarly, subjects in GOLD stage I (HR, 1.30; p = 0.05) and stage II (HR, 1.77; p < 0.0001) had increased all-cause mortality. When expanding GOLD stage 0 to comprise patients with any respiratory symptom in a sensitivity analysis, the HR for all-cause mortality increased (HR, 1.35; p = 0.03). CONCLUSION: There probably is an excess mortality among GOLD stage 0 subjects compared to symptom-free subjects; however, this should be interpreted cautiously and the results vary with the definition of the GOLD stage 0. Subjects in GOLD stage I or stage II had higher mortality than symptom-free subjects.
STUDY OBJECTIVES: To determine if the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 0 (subjects at risk for COPD) provides information about long-term mortality risk. DESIGN, SETTING, AND PARTICIPANTS: From 1972 to 1975, clinical, physiologic, and biochemical parameters including respiratory symptoms, spirometry, and physical fitness were measured in 1,999 healthy men aged 40 to 59 years in an occupational cohort, of whom 1,623 had acceptable spirometry findings. In a proportional hazards model with follow-up until 2000, we assessed all-cause mortality according to GOLD stage 0, I, II, and III compared with "normal" subjects, after adjusting for known risk factors and potential confounders. RESULTS: After 26 years (range, 25 to 27 years), 615 men (38%) had died. In multivariate proportional hazards models, GOLD stage 0 subjects had a nonsignificantly increased hazard of death (hazard ratio [HR], 1.19; p = 0.21) after adjustment for age, smoking, physical fitness, body mass index, systolic BP, and serum cholesterol. Similarly, subjects in GOLD stage I (HR, 1.30; p = 0.05) and stage II (HR, 1.77; p < 0.0001) had increased all-cause mortality. When expanding GOLD stage 0 to comprise patients with any respiratory symptom in a sensitivity analysis, the HR for all-cause mortality increased (HR, 1.35; p = 0.03). CONCLUSION: There probably is an excess mortality among GOLD stage 0 subjects compared to symptom-free subjects; however, this should be interpreted cautiously and the results vary with the definition of the GOLD stage 0. Subjects in GOLD stage I or stage II had higher mortality than symptom-free subjects.
Authors: Samuel Y Ash; Rola Harmouche; Rachel K Putman; James C Ross; Alejandro A Diaz; Gary M Hunninghake; Jorge Onieva Onieva; Fernando J Martinez; Augustine M Choi; David A Lynch; Hiroto Hatabu; Ivan O Rosas; Raul San Jose Estepar; George R Washko Journal: Chest Date: 2017-05-12 Impact factor: 9.410
Authors: Surya P Bhatt; Pallavi P Balte; Joseph E Schwartz; Byron C Jaeger; Patricia A Cassano; Paulo H Chaves; David Couper; David R Jacobs; Ravi Kalhan; Robert Kaplan; Donald Lloyd-Jones; Anne B Newman; George O'Connor; Jason L Sanders; Benjamin M Smith; Yifei Sun; Jason G Umans; Wendy B White; Sachin Yende; Elizabeth C Oelsner Journal: Ann Am Thorac Soc Date: 2022-08
Authors: Gonzalo Labarca; Andrea Bustamante; Gonzalo Valdivia; Rodrigo Díaz; Álvaro Huete; Paul Mac Nab; Laura Mendoza; Jaime Leppe; Carmen Lisboa; Fernando Saldías; Orlando Díaz Journal: BMJ Open Date: 2017-08-11 Impact factor: 2.692
Authors: Filip Mejza; Louisa Gnatiuc; A Sonia Buist; William M Vollmer; Bernd Lamprecht; Daniel O Obaseki; Pawel Nastalek; Ewa Nizankowska-Mogilnicka; Peter G J Burney Journal: Eur Respir J Date: 2017-11-22 Impact factor: 16.671
Authors: Helen Ilumets; Paula Rytilä; Ingel Demedts; Guy G Brusselle; Anssi Sovijärvi; Marjukka Myllärniemi; Timo Sorsa; Vuokko L Kinnula Journal: Int J Chron Obstruct Pulmon Dis Date: 2007
Authors: MeiLan K Han; Alvar Agusti; Bartolome R Celli; Gerard J Criner; David M G Halpin; Nicolas Roche; Alberto Papi; Robert A Stockley; Jadwiga Wedzicha; Claus F Vogelmeier Journal: Am J Respir Crit Care Med Date: 2021-02-15 Impact factor: 21.405